Beijing Beilu Pharmaceutical Hits Day High with 7.43% Surge

Beijing Beilu Pharmaceutical Co., Ltd. has experienced a significant uptick in its stock performance, gaining 7.43% on July 1, 2026. The stock reached an intraday high of CNY 8.28, marking a notable achievement in the small-cap pharmaceuticals and biotechnology sector. In terms of performance metrics, the company has shown resilience with a year-to-date increase of 3.78%, slightly outperforming the China Shanghai Composite, which stands at 3.62%. However, over the past year, Beijing Beilu's stock has faced challenges, reflecting a decline of 16.85%, contrasting sharply with the Composite's gain of 18.93%. Financially, the company reported a robust operating profit growth of 24.59% and a significant increase in net sales, reaching CNY 652.96 million, up 21.7%. The operating cash flow also peaked at CNY 255.83 million, indicating strong operational efficiency. With a return on equity of 3.36% and a price-to-book ratio of 1.33, Beijing Beilu maintains a fair valuation in the current market landscape.